alpha-Linolenic acid (ALA) is an omega-3 polyunsaturated fatty acid found in seed oils such as cranberry, strawberry, flax, and chia rather than a classic volatile essential-oil terpene. The current evidence base is strongest for identity, nutritional relevance, and skin-barrier-related research, including tissue-engineered skin work, animal studies, and a recent human oral-intake trial using an ALA-rich oil format. Those findings are useful for archive context, but they should be framed as ingredient and barrier-support research rather than medical treatment claims.
Chemical identity and composition
PubChem lists alpha-linolenic acid as CID 5280934 with formula C18H30O2 and the all-cis 18:3 omega-3 structure. In the archive, cranberry seed oil lists alpha-linolenic acid at 30-35% and strawberry seed oil lists it at 29.53%, making it a major fixed-oil identity marker rather than a trace constituent.
Aroma and practical use
- Use the recorded faint, fatty, oily descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A tissue-engineered skin study reported that combined alpha-linolenic acid and linoleic acid supplementation improved barrier function, reduced testosterone absorption through the reconstructed skin model, and shifted lipid mediator profiles toward normal-skin patterns.
A tissue-engineered skin study reported that combined alpha-linolenic acid and linoleic acid supplementation improved barrier function, reduced testosterone absorption through the reconstructed skin model, and shifted lipid mediator profiles toward normal-skin patterns.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2026 randomized, double-blind, placebo-controlled study reported that 2.5 g/day of diacylglycerol-enriched ALA oil for 8 weeks increased cheek hydration and improved several mild allergy-related symptom measures compared with placebo oil.
A 2026 randomized, double-blind, placebo-controlled study reported that 2.5 g/day of diacylglycerol-enriched ALA oil for 8 weeks increased cheek hydration and improved several mild allergy-related symptom measures compared with placebo oil.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
A 2024 obese-mouse study reported that oral linseed oil intake, used as an ALA-rich intervention, lowered transepidermal water loss, reduced erythema and epidermal thickening, and lowered inflammatory gene expression after UVB challenge.
A 2024 obese-mouse study reported that oral linseed oil intake, used as an ALA-rich intervention, lowered transepidermal water loss, reduced erythema and epidermal thickening, and lowered inflammatory gene expression after UVB challenge.
This experimental finding does not establish benefit, dose or safety in people using this blend.
An earlier hairless-mouse study reported that dietary ALA, but not topical ALA, more clearly suppressed UVB-induced skin injury compared with linoleic-acid-rich feeding conditions, highlighting route-dependent effects.
An earlier hairless-mouse study reported that dietary ALA, but not topical ALA, more clearly suppressed UVB-induced skin injury compared with linoleic-acid-rich feeding conditions, highlighting route-dependent effects.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedNo isolated-constituent IFRA-style dermal limit or phototoxicity warning was located for alpha-linolenic acid in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because alpha-linolenic acid is a highly unsaturated fatty acid, oxidation stability is a practical formulation concern even when biological tolerance is otherwise favorable.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Most located benefit-oriented studies used oral intake, mixed lipid supplementation, or whole ALA-rich oils rather than neat topical alpha-linolenic acid, so copy should avoid overextending those findings.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
epidermal lipid incorporation
In tissue-engineered skin, supplemental ALA was incorporated into phospholipid and triglyceride fractions and shifted lipid-mediator profiles toward those seen in normal skin.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
lower pro inflammatory skin signals
Animal data suggest higher skin alpha-linolenic acid levels can be associated with lower transepidermal water loss and lower expression of inflammatory markers such as Tnfalpha, Cox2, Mcp1, and Hmox1 in challenged skin.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- Much of the reviewed skin evidence involves oral intake or mixed fatty-acid systems rather than isolated topical alpha-linolenic acid.
- 2026-07-13 dermal-safety verification pass (Tisserand & Young monograph index, IFRA Standards 51st Amendment library, RIFM Fragrance Material Safety Resource, CIR Safety Assessment of Fatty Acids & Fatty Acid Salts) found no constituent-specific numeric dermal limit for alpha-linolenic acid; a CIR fatty-acids review reference surfaced a mention of in-chemico DPRA assay data flagging linoleic/linolenic acid as potential sensitizers, but the primary document could not be retrieved/confirmed in full during this pass, so sensitizing is left unchanged (null) rather than set from an unconfirmed secondary mention. dermal_limit_pct remains unverified and should not be treated as sourced.
- Because alpha-linolenic acid is primarily a fixed-oil fatty acid, direct aroma-descriptor literature is sparse compared with volatile terpenes.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.